-
112022.10NEWS
HanAll’s Licensed Partner in China Enters Sublicense Agreeme..
HanAll’s Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Devel..
-
112022.10NOTICE
HanAll Biopharma’s Licensed Partner in China Provides Update..
HanAll Biopharma’s Licensed Partner in China Provides Updates on Phase 3 Trial in Dry Eye Disease in..
-
052022.10NEWS
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the D..
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partn..
-
052022.10NEWS
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the D..
HanAll’s Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partn..
-
292022.07NEWS
HanAll Biopharma Reports Second Quarter 2022 Results and Pro..
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update
-
282022.04NEWS
HanAll Biopharma Reports First Quarter 2022 Results and Prov..
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update